National Audit of Breast Cancer in Older Patients: Annual Reports

National Audit of Breast Cancer in Older Patients: Annual Report 2021
HQIP 12 August 2021

• Based on data from women aged 50+ years diagnosed with breast cancer between January 2019 and 31 July 2020, this report reviews diagnoses and treatment patterns across England and Wales, taking the early months of the pandemic into consideration. Outcomes among women diagnosed between January 2014 and December 2018 were also examined within the report.

National Audit of Breast Cancer in Older Patients – 2020 Annual Report
HQIP 9 July 2020

• A report of the process and outcomes of care for 185,648 patients, aged 50 years and over, diagnosed with breast cancer between 1 January 2014 and 31 December 2018 in England and Wales. Information from the English Cancer Patient Experience Survey (CPES), completed by patients diagnosed in England in 2015 to 2018 is included.

National Audit of Breast Cancer in Older Patients: 2019 Annual Report
HQIP 9 May 2019

• A report of the process and outcomes of care for 147,162 patients, diagnosed with breast cancer between 1st January 2014 and 31st December 2017 in England and Wales. This is the first report using data linked from the English Cancer Patient Experience Survey (CPES) to the NABCOP patient-level data.

National Bowel Cancer Audit Annual Reports

National Bowel Cancer Audit (NBoCA) – Trends, characteristics and outcomes for patients diagnosed under 50 years old with metastatic colon cancer in England

HQIP 10 June 2021

• This short report looks at early onset colorectal cancer (EOCRC), which is defined as a diagnosis of colorectal cancer under the age of 50 years. The incidence of EOCRC appears to be increasing rapidly, and the reasons for this trend are poorly understood. This report therefore compares patient data for those under 50 years with older patients, where both groups were diagnosed with metastatic colon cancer between 01 April 2013 and 31 March 2018 in England.

National Bowel Cancer Audit Annual Report 2020

HQIP 10 December 2020

• Data on over 30,000 patients diagnosed with bowel cancer between 01 April 2018 and 31 March 2019.

National Bowel Cancer Audit Annual Report 2019
HQIP 9 January 2020

• Data on patients diagnosed with bowel cancer between 01 April 2017 and 31 March 2018. 
• For the first time, new indicators of return to theatre and robotic surgery are reported and the measure of adjuvant chemotherapy for stage III colon cancer is reported at trust/hospital level in England. The report discusses several key findings for care pathways, surgical care, survival, rectal cancer and National Cancer Registry data.

Variations in Demand across England for the Magnetic Resonance-Linac Technology, Simulated Utilising Local-level Demographic and Cancer Data in the Malthus Project.

Variations in Demand across England for the Magnetic Resonance-Linac Technology, Simulated Utilising Local-level Demographic and Cancer Data in the Malthus Project.
Clin Oncol (R Coll Radiol). 2021 Mar 25:S0936-6555(21)00095-9. doi: 10.1016/j.clon.2021.03.004.

• According to this model of demand and demand variations for magnetic resonance-linac (MR-linac) it could service 16% of England's fraction burden. The variations in simulated demand of the MR-linac highlight the requirement to use local-level data when planning to introduce a new technology.

Abstract

Cancer in Children, teenagers and young adults

Cancer in children, teenagers and young adults
National Cancer Registration and Analysis Service February 2021

• Data from the four UK national cancer registries to describe the incidence, survival and mortality from cancer diagnosed among children, teenagers and young adults resident in the United Kingdom. The analysis relates to children and young people who were diagnosed with cancer under the age of 25 during the 20-year period of 1997-2016. Includes survival charts 0-14yrs, 15-24 years and 0-24 years.

Primary liver cancer in the UK: Incidence, incidence-based mortality, and survival by subtype, sex, and nation

Primary liver cancer in the UK: Incidence, incidence-based mortality, and survival by subtype, sex, and nation
JHEP Reports 3(2) 100232, 19 January 2021 DOI:https://doi.org/10.1016/j.jhepr.2021.100232

• Analysis of data on primary liver cancers diagnosed during 1997–2017 obtained from population-based, nationwide registries in the UK indicates that incidence and mortality rates have rapidly increased between 1997 and 2014 (rate of increase has plateaued since around 2014); hepatocellular carcinoma incidence and mortality rates were highest in Scottish men; survival has improved, particularly for hepatocellular carcinoma, but remains poor.

National Prostate Cancer Audit Annual Report

National Prostate Cancer Audit Annual Report 2020

HQIP 14 January 2021

• 52,580 men were diagnosed with prostate cancer in England and Wales between 1 April 2018 and 31 March 2019. The number of men diagnosed rose quite significantly in the diagnosis period compared to the previous year: by 23% in both England (40,429 to 49,804) and Wales (2,239 to 2,776). This is a larger year-on-year increase than seen previously and might be explained by media coverage of two high-profile individuals with prostate cancer in 2018.

National Prostate Cancer Audit Annual Report 2019
HQIP 9 January 2020

• Results of the NPCA Prospective Audit in England and Wales for men diagnosed from 1 April 2017 to 31 March 2018. A breakdown of results at the level of each Trust and specialist MDT are provided in the appendices.
• Report also available on the National Prostate Cancer Audit website, with patient resources

NHS Cancer Programme: Cancer services recovery plan

NHS Cancer Programme: Cancer services recovery plan
NHS England 14 December 2020

• Phase 3 of the response to the pandemic around cancer services outlines full recovery of NHS cancer services in England.

National Oesophago-Gastric Cancer Audits

National Oesophago-Gastric Cancer Audit 2020
HQIP 10 December 2020

• The primary focus of the 2020 Annual Report is the care received by adult patients diagnosed between April 2017 and March 2019 and their outcomes.

National Oesophago-Gastric Cancer Audit 2019

HQIP 13 December 2019

• This audit collects prospective data on adult patients diagnosed in England and Wales with invasive epithelial cancer of the oesophagus, gastro-oesophageal junction (GOJ) or stomach, and patients diagnosed with high grade dysplasia (HGD) of the oesophagus. This report describes the care received by patients diagnosed between April 2016 and March 2018 and their outcomes.

Cancer Quality of Life Survey

Cancer Quality of Life Survey 

• A national survey run by NHS England in partnership with the National Cancer Registration and Analysis Service (NCRAS) based at Public Health England (PHE).
• From 2020, people in England who have had a breast, prostate or colorectal (bowel) cancer diagnosis are being asked to complete the survey around 18 months after diagnosis.
• Results of the survey will be available from 2021 and will be published on the ‘Cancer Data’ website (https://www.cancerdata.nhs.uk/ ).

Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortalityin people with cancer and multimorbidity

Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort study.
BMJ Open. 2020 Nov 17;10(11):e043828. doi: 10.1136/bmjopen-2020-043828.

• Background mortality risks for 24 cancers with and without COVID-19-relevant comorbidities were obtained from population-based primary care cohort (Clinical Practice Research Datalink) on 3 862 012 adults in England. Dramatic reductions were detected in the demand for, and supply of, cancer services which have not fully recovered with lockdown easing. These may contribute, over a 1-year time horizon, to substantial excess mortality among people with cancer and multimorbidity.

Radiology: GIRFT Programme National Specialty Report

Radiology: GIRFT Programme National Specialty Report
GIRFT 10 November 2020

• This report, a companion to Sir Mike Richards’ recent review of diagnostic services Diagnostics: Recovery and Renewal, examines ways of meeting the ever-increasing demand on radiology units in England at the same time as shaping a better service for those who use it.

NICE COVID-19 rapid guidelines

COVID-19 rapid reviews of interest to Specialised commissioning
NICE 
Check NICE website for new guidelines and updates

• COVID-19 rapid guideline: haematopoietic stem cell transplantation (NG164) 1 April 2020 Updated 10 February 2021
• COVID-19 rapid guideline: delivery of systemic anticancer treatments (NG161) 20 March 2020 Updated 12 February 2021
• COVID-19 rapid guideline: dialysis service delivery (NG160) updated 11 September 2020
• COVID-19 rapid guideline: critical care in adults (NG159) updated: 12 February 2021
• COVID 19 rapid guideline: renal transplantation (NG178) 19 June 2020 updated 19 August 2020
• COVID-19 rapid guideline: arranging planned care in hospitals and diagnostic services
  NICE guideline [NG179] 27 July 2020
  
  • The purpose of this guideline is to help healthcare professionals deliver efficient planned care while minimising the risk of COVID-19 in the context of increasing or decreasing local prevalence. It also aims to help patients make decisions about their planned care. It is for adults, young people and children in hospitals and diagnostic settings.
• COVID-19 rapid guideline: delivery of radiotherapy (NG162) 28 March 2020 updated 12 february 2021
• COVID-19 rapid guideline: cystic fibrosis (NG170) 09 April 2020 updated 7 October 2020
• COVID-19 rapid guideline: interstitial lung disease (NG177) 15 May 2020

Cancer 62 Day Patient Target List to include waiting list breakdown

Cancer 62 Day Patient Target List (CANPTL62)
NHS Digital

• The 'Cancer 62 Day Patient Target List' (CANPTL62) collection is a weekly snapshot which shows the number of patients on the cancer 62-day pathway, who are at risk of breaching the 62-day standard (two month/62-day wait from urgent GP referral to first definitive treatment). From the 23 November 2020, this collection has been remodelled to also include waiting list breakdown by suspected tumour groups 62-day screening, consultant upgrades and further granularity about the start of treatment.

Exploring international differences in ovarian cancer treatment: a comparison of clinical practice guidelines and patterns of care.

Exploring international differences in ovarian cancer treatment: a comparison of clinical practice guidelines and patterns of care.
International Journal of Gynecologic Cancer 2 November 2020;30:1748-1756.

• Comparisons of clinical practice guidelines and patterns of care across seven high-income countries (Norway, Australia, Denmark, Canada, UK and new Zealand) suggest international variations in ovarian cancer treatment. Characteristics relating to countries with higher stage-specific survival included higher reported rates of primary surgery; willingness to undertake extensive/ultra-radical procedures; greater access to high-cost drugs; and auditing.

Early Detection and Diagnosis of Cancer Roadmap

 Early Detection and Diagnosis of Cancer Roadmap
Cancer Research UK October 2020

• The Cancer Roadmap aims to unite fragmented efforts across the UK to drive progress in early detection and diagnosis.

Cancer survival in England for patients diagnosed between 2014 and 2018, and followed up until 2019

Cancer survival in England for patients diagnosed between 2014 and 2018, and followed up until 2019
PHE 30 October 2020

• Cancer survival statistics for adults and children by stage at diagnosis and by different geographical variations.
• Main points
• Melanoma of the skin had the highest age-standardised net survival for 1-year in both males (97.6%) and females (98.8%) and for 5-year in males (90.1%) and females (94.5%) for diagnoses between 2014 and 2018.
• Pancreatic cancer had the lowest age-standardised net survival for 1-year in males (25.3%) and females (26.6%), and for 5-year in females (8.2%) for diagnoses between 2014 and 2018. For males, the lowest 5-year survival is in mesothelioma cancer (6.7%).
• We provide survival by stage estimates for 23 cancer sites. Stage data is complete for 86.8% of diagnoses in 2014 to 2018.
• Childhood cancer survival has continued to improve for 1-, 5- and 10-years, with the 5-year survival seeing the greatest improvement over time; an increase of 7.4 percentage points, from 77.2% in 2001 to 84.6% predicted for children diagnosed in 2019.
• For Cancer Alliances (CAs), the difference between the minimum and maximum 1-year survival estimates varies from 1.5 percentage points for breast cancer (females only) to 13.1 percentage points for brain cancer (all persons).
• All graphs can be found on the interactive R Shiny App.

Mortality due to cancer treatment delay: systematic review and meta-analysis

Mortality due to cancer treatment delay: systematic review and meta-analysis
BMJ 2020; 371 :m4087 16 October 2020

• Analysis of 34 studies of the association of cancer treatment delay and mortality concludes that "even a four week delay of cancer treatment is associated with increased mortality across surgical, systemic treatment, and radiotherapy indications for seven cancers." 

Abstract

National Prostate Cancer Audit: Short Report 2020 - variation in the treatment of high-risk or locally advanced prostate cancer

National Prostate Cancer Audit: Short Report 2020
HQIP 8 October 2020

• This short report examines geographical variation in the management of high-risk or locally advanced prostate cancer in England, explores determinants for receipt of treatment, establishes between-hospital variation and investigates possible reasons for this variation.
• The latest figures from the National Prostate Cancer Audit (NPCA) show that in 2017-18 over 47,000 men were diagnosed with prostate cancer in England and that 41% had high risk or locally advanced disease. Approximately one third of men with high-risk or locally advanced prostate cancer do not receive radical surgery or radiotherapy treatment in England and Wales. Many factors are implicated in this potential ‘under-treatment’ but little is known about the between-hospital variation.

Reducing wait time for administration of systemic anticancer treatment (SACT) in a hospital outpatient facility

Reducing wait time for administration of systemic anticancer treatment (SACT) in a hospital outpatient facility
BMJ Open Quality 2020;9:e000904. doi: 10.1136/bmjoq-2019-000904

• LEAN principles were used to redesign a systemic anticancer treatment service [Scotland] resulting in reduced average appointment time and in positive patient experience.

Cancer in the UK 2020: Socio-economic deprivation

Cancer in the UK 2020: Socio-economic deprivation
Cancer Research UK 30 September 2020

• This report examines the link between socio-economic deprivation and cancer. 
• “People from more deprived areas are not only more likely to get cancer, they’re more likely to be diagnosed at a late stage for certain cancer types, and have trouble accessing cancer services."
• Full report here.